Hem › Icke-småcellig lungcancer › Colorado › Grand Junction
Kliniska studier för Icke-småcellig lungcancer i Grand Junction, CO
8 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Grand Junction (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekryterarFas 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RekryterarFas 3
- Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132), Grand Junction
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekryterarFas 3
- Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
- Intermountain Health St. Mary's Regional Hospital, Grand Junction
- Intermountain Health, Grand Junction
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekryterarFas 3
- Local Institution - 0500, Grand Junction
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RekryterarFas 3
- Clinical Study Site, Grand Junction
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekryterarFas 3
- Research Site, Grand Junction
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
RekryterarFas 3
- Intermountain Health St. Mary's Regional Hospital ( Site 0116), Grand Junction
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekryterarFas 3
- Saint Mary's Hospital and Regional Medical Center, Grand Junction
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andra studier i Grand Junction
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.